BR9916860A - Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma - Google Patents

Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma

Info

Publication number
BR9916860A
BR9916860A BR9916860-0A BR9916860A BR9916860A BR 9916860 A BR9916860 A BR 9916860A BR 9916860 A BR9916860 A BR 9916860A BR 9916860 A BR9916860 A BR 9916860A
Authority
BR
Brazil
Prior art keywords
blood
preparation
dosage unit
glycerides
same
Prior art date
Application number
BR9916860-0A
Other languages
English (en)
Inventor
William Lawrence Stone
Andreas M Papas
Original Assignee
Eastman Chem Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Chem Co filed Critical Eastman Chem Co
Publication of BR9916860A publication Critical patent/BR9916860A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

"MéTODO DE REDUZIR COLESTEROL DO SANGUE E/OUTRIGLICERìDIOS DO SANGUE EM UM INDIVìDUO MAMìFERO,PREPARAçãO EM FORMA DE UNIDADE DE DOSAGEM,E,CONJUNTO PARA ADMINISTRAR ORALMENTE A MESMA".Colesterol do sangue e/ou triglicerídeos do sangue são reduzidosem um indivíduo marmífero administrando-se uma quantidadeeficaz de terc-butilhidroquinona ou um sal desta. O indivíduomamífero é de preferência humano. Adicionalmente, a preparaçãode terc-butilhidroquinona em forma de unidade de dosagem éfornecida para reduzir colesterol do sangue e/ou triglicerídeos dosangue. A preparação é vantajosamente projetada paraadministração oral.
BR9916860-0A 1999-01-11 1999-12-17 Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma BR9916860A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/228,092 US6020383A (en) 1999-01-11 1999-01-11 Method for reducing blood cholesterol and/or blood triglycerides
PCT/US1999/030369 WO2000041504A2 (en) 1999-01-11 1999-12-17 Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides

Publications (1)

Publication Number Publication Date
BR9916860A true BR9916860A (pt) 2001-10-30

Family

ID=22855753

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916860-0A BR9916860A (pt) 1999-01-11 1999-12-17 Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma

Country Status (6)

Country Link
US (1) US6020383A (pt)
EP (1) EP1140051A2 (pt)
JP (1) JP2002534445A (pt)
CN (1) CN1333681A (pt)
BR (1) BR9916860A (pt)
WO (1) WO2000041504A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) * 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US6436406B1 (en) 2000-06-15 2002-08-20 A. Glenn Braswell Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis
US6623734B2 (en) * 2000-06-22 2003-09-23 Soft Gel Technologies, Inc. Super absorption coenzyme Q10
US6855733B2 (en) * 2001-01-24 2005-02-15 Soft Gel Technologies, Inc. Formulation and manufacturing process for coenzyme Q10 soft gel capsules
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
EP1670325A1 (en) 2003-09-29 2006-06-21 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US8124072B2 (en) * 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
ATE357932T1 (de) * 2003-12-22 2007-04-15 Alcon Inc Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
WO2005063249A1 (en) * 2003-12-22 2005-07-14 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
FR2868313B1 (fr) * 2004-03-31 2008-08-15 Servier Lab Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
JP2007289001A (ja) * 2004-05-10 2007-11-08 Toyo Shinyaku:Kk ポリフェノールを含有する食品
US7284385B2 (en) * 2004-09-16 2007-10-23 Hess Spencer W Pre-dried air reactivation for diesel fuel heated dessicant reactivator
US8300698B2 (en) * 2006-10-23 2012-10-30 Qualcomm Incorporated Signalling of maximum dynamic range of inverse discrete cosine transform
US8343541B2 (en) * 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
TWI518094B (zh) * 2011-12-26 2016-01-21 Univ Beijing Peking Wbl Biotech Co Ltd One kind of derivatives of sterols, their preparation and use
CN110585180A (zh) * 2019-09-25 2019-12-20 中国热带农业科学院环境与植物保护研究所 一种治疗百草枯急性中毒特异性解毒药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
US5116629A (en) * 1990-10-24 1992-05-26 General Mills, Inc. Processed meat products containing fish oils stabilized with fructose
US5338549A (en) * 1992-12-21 1994-08-16 The Procter & Gamble Company Powdered psyllium drink mix compositions containing antioxidant
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
WO1998022418A1 (en) * 1996-11-20 1998-05-28 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents

Also Published As

Publication number Publication date
WO2000041504A2 (en) 2000-07-20
EP1140051A2 (en) 2001-10-10
WO2000041504A3 (en) 2000-11-09
US6020383A (en) 2000-02-01
JP2002534445A (ja) 2002-10-15
CN1333681A (zh) 2002-01-30

Similar Documents

Publication Publication Date Title
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
US6221377B1 (en) Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
BR0015284A (pt) Formulações de hidrocodona de liberação controlada
ATE522211T1 (de) Stabilisierte fibrat-mikropartikel
CO4970819A1 (es) Tratamiento de disfuncion sexual femenina en una hembra humana
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ES2134340T3 (es) Uso de acido beta-hidroxi-beta-metilbutirico para promover la retencion de nitrogeno en los seres humanos.
SG54210A1 (en) Oral composition for the treatment of bowel inflammatory bowel diseases
KR950703951A (ko) 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac)
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
MY124465A (en) Reduction of infarct volume using citicoline
HK1026637A1 (en) Compositions for administering taxanes orally to human patients and their use
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
JP2002540148A5 (pt)
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
CA2373296C (en) Combination of nicotinic acid or nicotinamide with riboflavin for the treatment of pruritus, itching and inflammation disorders
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
BR0009875A (pt) Uso de n-acetilcisteìna para a preparação de um medicamento adequado para a administração intravenosa para prevenir a carga oxidativa em pacientes que sofreram diálise
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
KR890007728A (ko) 진통제 제조방법

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]